PTGS2 and colorectal neoplasm: PTGS2 has been considered an ideal target for colorectal tumor chemoprevention [3,4], but the cardiotoxicity associated to the specific PTGS2 inhibitor Celecoxib determined an unfavorable cost/benefit ratio for the chemoprevention of the normal population.